Swissmedic - Swiss Agency for Therapeutic Products

08/28/2026 | News release | Distributed by Public on 08/28/2026 02:09

DHPC – Gabapentin Viatris (gabapentinum)

28.08.2026

Préparation Gabapentin Viatris 300 mg, 50 gélules
No d'autorisation 61264
Principe actif gabapentinum
Titulaire de l'autorisation Viatris Pharma GmbH
Lot concernés 3258293B

Pour le lot 3258293B de Gabapentin Viatris 300 mg, 50 gélules, les gélules portent l'inscription« Neurontin® 300 mg VLE » imprimée en bleu, alors que le marquage correct devrait être« G 5027 » imprimé en gris.

Vous trouverez de plus amples informations dans le courrier de l'entreprise.

Swissmedic - Swiss Agency for Therapeutic Products published this content on August 28, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on August 28, 2026 at 08:09 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]